I picked this up on Twitter from a tweet done by the account "DRG Tokyo" on April 4th.   The tweet included a link to a March 17th PR put out by an outfit called "Decision Resource Group":

http://www.prnewswire.com/news-releases/pcsk9-inhibitors-improve-patient-outcomes-but-will-that-convince-payers-to-pay-for-them-300424733.html

Apabetalone is mentioned in the PR:  

• Several new emerging therapies with novel MOAs will also stimulate market growth, despite being used in later lines of therapy. These products include Esperion Therapeutics' bempedoic acid (ETC-1002), Merck's anacetrapib, and Resverlogix's apabetalone (RVX-208).

My appologies if this has already been discussed, but I don't recall having seen it.....